Baron S, Tyring S K, Fleischmann W R, Coppenhaver D H, Niesel D W, Klimpel G R, Stanton G J, Hughes T K
Department of Microbiology, University of Texas Medical Branch, Galveston 77550.
JAMA. 1991 Sep 11;266(10):1375-83. doi: 10.1001/jama.266.10.1375.
The interferons (IFN) are one of the body's natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteins (alpha, beta, and gamma), which then induce the antiviral, antimicrobial, antitumor, and immunomodulatory actions of IFN. Recent advances have led to Food and Drug Administration approval of five clinical indications for IFN. Interferon alfa is approved for hairy-cell leukemia, condyloma acuminatum, Kaposi's sarcoma in the acquired immunodeficiency syndrome, and non-A, non-B (type C) viral hepatitis. Interferon gamma has properties distinctive from those of IFNs alpha and beta and is approved as an immunomodulatory treatment for chronic granulomatous disease. Promising clinical results with IFNs have also been reported for basal cell carcinoma, chronic myelogenous leukemia, cutaneous squamous cell carcinoma, early human immunodeficiency virus infection, hepatitis B, and laryngeal papillomatosis. Future clinical uses of IFNs may emphasize combination therapy with other cytokines, chemotherapy, radiation, surgery, hyperthermia, or hormones.
干扰素（IFN）是机体对微生物、肿瘤和抗原等外来成分的天然防御反应之一。干扰素反应始于干扰素蛋白（α、β和γ）的产生，这些蛋白随后诱导干扰素的抗病毒、抗菌、抗肿瘤和免疫调节作用。最近的进展已使美国食品药品监督管理局批准了干扰素的五种临床应用指征。α干扰素被批准用于治疗毛细胞白血病、尖锐湿疣、获得性免疫缺陷综合征中的卡波西肉瘤以及非甲非乙型（丙型）病毒性肝炎。γ干扰素具有与α和β干扰素不同的特性，被批准作为慢性肉芽肿病的免疫调节治疗药物。对于基底细胞癌、慢性粒细胞白血病、皮肤鳞状细胞癌、早期人类免疫缺陷病毒感染、乙型肝炎和喉乳头状瘤，也有关于干扰素的临床效果良好的报道。干扰素未来的临床应用可能会侧重于与其他细胞因子、化疗、放疗、手术、热疗或激素的联合治疗。
